{"id":13188,"date":"2023-04-25T00:00:00","date_gmt":"2023-04-25T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma-a-multi-site-population-based-cohort-study\/"},"modified":"2023-07-24T14:36:32","modified_gmt":"2023-07-24T18:36:32","slug":"hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/","title":{"rendered":"Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study"},"content":{"rendered":"

Background<\/strong> \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial.<\/p>\n

Objective<\/strong> \u2014 To determine whether HCTZ is associated with an increased risk of skin cancer compared with angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs).<\/p>\n

Methods<\/strong> \u2014 Two new-user, active comparator cohorts were assembled using six Canadian databases. Site-specific hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using standardized morbidity ratio weighted Cox proportional hazard models and pooled using random-effects meta-analysis.<\/p>\n

Results<\/strong> \u2014 HCTZ was not associated with an overall increased risk of keratinocyte carcinoma compared with ACEIs or CCBs, although increased risks were observed with longer durations (\u226510 years; HR: 1.12; 95% CI: 1.03-1.21) and higher cumulative doses (\u2265100,000 mg; HR: 1.49; 95% CI: 1.27-1.76). For melanoma, there was no association with ACEIs, but a 32% increased risk with CCBs (crude incidence rates: 64.2 vs. 58.4 per 100,000 person-years; HR: 1.32; 95% CI: 1.19-1.46; estimated number needed to harm at 5 years of follow-up: 1,627 patients), with increased risks with longer durations and cumulative doses.<\/p>\n

Limitations<\/strong> \u2014 Residual confounding due to the observational design.<\/p>\n

Conclusions<\/strong> \u2014 Increased risks of keratinocyte carcinoma and melanoma were observed with longer durations of use and higher cumulative doses of HCTZ.<\/p>\n","protected":false},"excerpt":{"rendered":"

Background \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. Objective \u2014 To determine whether HCTZ is associated with an increased risk of skin cancer compared with angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs). Methods \u2014 Two new-user, active comparator cohorts were assembled using six Canadian databases. Site-specific hazard ratios (HRs) […]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[38,56],"migration-helper-qa-sample-set":[],"class_list":["post-13188","journal_article","type-journal_article","status-publish","hentry","topic-cancer-and-cancer-screening","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Azoulay L, St-Jean A, Dahl M, Quail J, Aibibula W, Brophy JM, Chan AW, Bresee L, Carney G, Eltonsy S, Tamim H, Paterson JM, Platt RW; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. J Am Acad Dermatol<\/em>. 2023; Apr 25 [Epub ahead of print].","source_url":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.035","ices_scientist":[1100,1196],"site":[6733],"research_program":[6746],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"A9DD49E8-DBBD-4D17-8152-728D8DC284AC","sitecore_item_name":"Hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma","sitecore_field_values":"{\r\n \"Title\": \"Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study\",\r\n \"Short title\": \"Hydrochlorothiazide use and risk of\",\r\n \"Summary\": \"The study aim was to find if hydrochlorothiazide is associated with an increased risk of skin cancer compared with angiotensin-converting enzyme inhibitors and calcium channel blockers \",\r\n \"Citation\": \"

Azoulay L, St-Jean A, Dahl M, Quail J, Aibibula W, Brophy JM, Chan AW, Bresee L, Carney G, Eltonsy S, Tamim H, Paterson JM, Platt RW; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. J Am Acad Dermatol<\/em>. 2023; Apr 25 [Epub ahead of print]. DOI: https:\/\/doi.org\/10.1016\/j.jaad.2023.04.035<\/a><\/p>\",\r\n \"Abstract\": \"

Background<\/strong> — The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial.<\/p>n

Objective<\/strong> — To determine whether HCTZ is associated with an increased risk of skin cancer compared with angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs).<\/p>n

Methods<\/strong> — Two new-user, active comparator cohorts were assembled using six Canadian databases. Site-specific hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using standardized morbidity ratio weighted Cox proportional hazard models and pooled using random-effects meta-analysis.<\/p>n

Results<\/strong> — HCTZ was not associated with an overall increased risk of keratinocyte carcinoma compared with ACEIs or CCBs, although increased risks were observed with longer durations (≥10 years; HR: 1.12; 95% CI: 1.03-1.21) and higher cumulative doses (≥100,000 mg; HR: 1.49; 95% CI: 1.27-1.76). For melanoma, there was no association with ACEIs, but a 32% increased risk with CCBs (crude incidence rates: 64.2 vs. 58.4 per 100,000 person-years; HR: 1.32; 95% CI: 1.19-1.46; estimated number needed to harm at 5 years of follow-up: 1,627 patients), with increased risks with longer durations and cumulative doses.<\/p>n

Limitations<\/strong> — Residual confounding due to the observational design.<\/p>n

Conclusions<\/strong> — Increased risks of keratinocyte carcinoma and melanoma were observed with longer durations of use and higher cumulative doses of HCTZ.<\/p>\",\r\n \"ICES Scientists\": \"{4A1034A0-5248-46A2-805E-20FBC57B1237}|{A8EA74FF-4975-4A0A-953D-EC1881EBD1B4}\"\r\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2023\/April\/Hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma"},"yoast_head":"\nICES | Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study<\/title>\n<meta name=\"description\" content=\"Background \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. Objective \u2014 To determine whether HCTZ is associated\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study\" \/>\n<meta property=\"og:description\" content=\"Background \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. Objective \u2014 To determine whether HCTZ is associated\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-24T18:36:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\\\/\",\"name\":\"ICES | Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2023-04-25T04:00:00+00:00\",\"dateModified\":\"2023-07-24T18:36:32+00:00\",\"description\":\"Background \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. Objective \u2014 To determine whether HCTZ is associated\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study","description":"Background \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. Objective \u2014 To determine whether HCTZ is associated","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study","og_description":"Background \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. Objective \u2014 To determine whether HCTZ is associated","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-07-24T18:36:32+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/","name":"ICES | Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2023-04-25T04:00:00+00:00","dateModified":"2023-07-24T18:36:32+00:00","description":"Background \u2014 The association between hydrochlorothiazide (HCTZ) and skin cancer remains controversial. Objective \u2014 To determine whether HCTZ is associated","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/hydrochlorothiazide-use-and-risk-of-keratinocyte-carcinoma-and-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multi-site population-based cohort study"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/13188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1196"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1100"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=13188"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=13188"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=13188"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=13188"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=13188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}